Alamar Biosciences Partners With GSK on Proteomic Study
Alamar Biosciences said it will use its Nulisa platform to study circulating protein signatures and disease progression with GSK.
Alamar Biosciences said it will use its Nulisa platform to study circulating protein signatures and disease progression with GSK.